SNC-80 is an opioid analgesic compound that selectively activates μ–δ opioid receptor heteromers[1] and is used primarily in scientific research.[2] Discovered in 1994, SNC-80 was a pioneering non-peptide compound regarded as a highly selective agonist for the δ-opioid receptor.[3]
Clinical data | |
---|---|
Other names | SNC-80 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H39N3O2 |
Molar mass | 449.639 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
SNC-80 was the first non-peptide compound developed that was regarded as a highly selective agonist for the δ-opioid receptor.[4] It has been shown to produce useful analgesic,[5] antidepressant[6] and anxiolytic effects in animal studies,[7][8] but its usefulness is limited by producing convulsions at high doses,[9] and so SNC-80 is not used medically, although it is a useful compound in scientific research.
References
edit- ^ Metcalf MD, Yekkirala AS, Powers MD, Kitto KF, Fairbanks CA, Wilcox GL, Portoghese PS (July 2012). "The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors". ACS Chemical Neuroscience. 3 (7): 505–9. doi:10.1021/cn3000394. PMC 3399572. PMID 22860219.
- ^ Calderon SN, Coop A (2004). "SNC 80 and related delta opioid agonists". Current Pharmaceutical Design. 10 (7): 733–42. doi:10.2174/1381612043453054. PMID 15032699.
- ^ Calderon SN, Rothman RB, Porreca F, Flippen-Anderson JL, McNutt RW, Xu H, et al. (July 1994). "Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist". Journal of Medicinal Chemistry. 37 (14): 2125–8. doi:10.1021/jm00040a002. PMID 8035418.
- ^ Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, et al. (April 1995). "SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist". The Journal of Pharmacology and Experimental Therapeutics. 273 (1): 359–66. PMID 7714789.
- ^ Gallantine EL, Meert TF (July 2005). "A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80". Basic & Clinical Pharmacology & Toxicology. 97 (1): 39–51. doi:10.1111/j.1742-7843.2005.pto_97107.x. PMID 15943758.
- ^ Jutkiewicz EM, Rice KC, Traynor JR, Woods JH (November 2005). "Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats". Psychopharmacology. 182 (4): 588–96. doi:10.1007/s00213-005-0138-9. PMC 1307499. PMID 16163520.
- ^ Perrine SA, Hoshaw BA, Unterwald EM (April 2006). "Delta opioid receptor ligands modulate anxiety-like behaviors in the rat". British Journal of Pharmacology. 147 (8): 864–72. doi:10.1038/sj.bjp.0706686. PMC 1760715. PMID 16491101.
- ^ Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (July 2004). "Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents". Journal of Pharmacological Sciences. 95 (3): 374–80. doi:10.1254/jphs.FPJ04014X. PMID 15272214.
- ^ Danielsson I, Gasior M, Stevenson GW, Folk JE, Rice KC, Negus SS (October 2006). "Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys". Pharmacology, Biochemistry, and Behavior. 85 (2): 428–34. doi:10.1016/j.pbb.2006.09.012. PMC 1820742. PMID 17112570.